AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01484912
Drug: STA-2
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:~STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Trial: NCT01484912
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:~Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state.
Trial: NCT04314336
Drug: Drug and Therapeutics Committee
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cost minimisation analysis of results of the drug and therapeutics committee before and after clinical pharmacist involvement
Trial: NCT01089062
Drug: MAP0004
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
Trial: NCT01089062
Drug: IV Placebo (Saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
Trial: NCT01089062
Drug: Placebo Inhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
Trial: NCT01969123
Drug: Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01969123
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02367183
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01175291
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil \[5-FU\] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
Trial: NCT02682901
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-active placebo for cycloset
Trial: NCT03870555
Drug: TAK-954 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-954 placebo-matching infusion intravenous.
Trial: NCT02067338
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
Trial: NCT03391180
Drug: ICON Remineralization
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A material used for the Remineralization of white spot lesions.
Trial: NCT03680105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be normal saline. To maintain the blind, a sleeve will cover the infusion bag and line such that the appearance will be identical to RJX administration.
Trial: NCT00598104
Drug: QAX576
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00598104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01774604
Drug: Indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg Indomethacin PR x 1
Trial: NCT01774604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04446000
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A solution matching the excipient profile of CSL730 without the active substance
Trial: NCT04382339
Drug: SOF/RBV/PegINFα-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF: block the hepatitis C NS5B protein. RBV: a nucleoside inhibitor PegINFα-2: chemically modified form of the standard interferon that treats hepatitis C
Trial: NCT03492138
Drug: ONC201
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 625mg
Trial: NCT00119106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04379024
Drug: DUAVEE 0.45Mg-20Mg Tablet
RxNorm normalized name: DUAVEE 0.45mg-20mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule daily for 6 months (+/- 1 month)
Trial: NCT04476069
Drug: IBUPROFEN
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given to children 30 minutes before extraction / orally for one time only
Trial: NCT03469375
Drug: modified-FOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LAPC patients with mFOLFIRINOX-based neoadjuvant therapy or not was set as the main intervention
Trial: NCT01053585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo single 'dose' 90 minutes prior to study
Trial: NCT00790985
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: antiinflammatory drug
Trial: NCT02809937
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: normal saline infusion
Trial: NCT03470441
Drug: FDY-5301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDY-5301 will be administered once, intravenously, by a healthcare professional. Dosage will be administered on a body weight basis, according to treatment assignment and using the subject's body weight determined on the dose administration day.
Trial: NCT04564937
Drug: SCT510A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCT510A of 0.625mg、1.25mg、2.0mg、2.5mg,IVT
Trial: NCT00440219
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill identical to Prednisone 10 days once daily pre-op
Trial: NCT04345107
Drug: SY-009 matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SY-009 matching placebo
Trial: NCT00525213
Drug: Rob 803
RxNorm normalized name: CATHETER,ROB-NEL 20FR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two capsules per day during 12 weeks
Trial: NCT00525213
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two capsules per day during 12 weeks
Trial: NCT00000245
Drug: Desipramine
RxNorm normalized name: Desipramine
DrugBank: Desipramine (DB01151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04168398
Drug: Combination drug
RxNorm normalized name: combination drugs used in erectile dysfunction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation
Trial: NCT00096070
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00801632
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg infusion on days -5, -4
Trial: NCT00474513
Drug: GSK239512
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03454620
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GC1118 combination with FOLFIRI
Trial: NCT00937196
Drug: Placebo globuli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo globuli administered together with verbal suggestions of a hypotensive drug effect
Trial: NCT00392041
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill qpm for 12 weeks
Trial: NCT02272270
Drug: Minocycline with chemoradiation (temozolomide and radiation therapy)
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
Trial: NCT00801632
Drug: corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
Trial: NCT04243681
Drug: Standard of care for Cirrhosis management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs used for Cirrhosis management such as Diuretics, Hepatoprotective agents and Lactulose
Trial: NCT01452828
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two separate infusions of 200 mg
Trial: NCT01452828
Drug: TR-701 FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion, 200 mg daily for 7 days
Trial: NCT03198208
Drug: Fentanyl dose administration
RxNorm normalized name: fentanyl Metered Dose Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02693587
Drug: Misodel and Angusta
RxNorm normalized name: Laminaria angustata extract
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00615823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
Trial: NCT00730405
Drug: Placebo 400 mg
RxNorm normalized name: placebo 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 36 weeks
Trial: NCT03851705
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Trial: NCT03851705
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile normal saline (0.9% sodium chloride in water for injection)
Trial: NCT00796198
Drug: Xalatan+Cosopt
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
Trial: NCT00821353
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
Trial: NCT00216736
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose oral placebo at ED discharge
Trial: NCT00857038
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline tablets, 100mg daily
Trial: NCT00857038
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets 100mg
Trial: NCT01191398
Drug: Normal saline 0.9%
RxNorm normalized name: BD Posiflush Normal Saline 0.9% Prefilled Syringe Solution for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
Trial: NCT03815305
Drug: Topical CA
RxNorm normalized name: Topical Cake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% centella asiatica ointment
Trial: NCT00230737
Drug: Melatonin 0.4 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230737
Drug: Melatonin 4.0 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00230737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00440505
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
Trial: NCT00836485
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control is a placebo patch that contains only the inactive ingredients of ketotifen.
Trial: NCT00158158
Drug: Usual Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: If unable to quit at quit date, offered usual care to set another quit date.
Trial: NCT02128308
Drug: Levofloxacin and Streptomycin added
RxNorm normalized name: streptomycin and isoniazid
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02128308
Drug: Moxifloxacin and Kanamycin added
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00887757
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.~325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.~This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
Trial: NCT02351700
Drug: IV Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Placebo intraoperatively and postoperatively
Trial: NCT00838136
Drug: Lamictal® 25 mg Chewable Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 25 mg, single-dose fed
Trial: NCT00841542
Drug: Norvasc®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Tablet
Trial: NCT00217763
Drug: 3APS
RxNorm normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02307994
Drug: 75IU uFSH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02027337
Drug: 20 mcg ethinylestradiol /3 mg drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Trial: NCT03954600
Drug: Placebos (125 mg)
RxNorm normalized name: placebo 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 125 mg oral capsules
Trial: NCT00135122
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
Trial: NCT02925494
Drug: Estradiol/Norethindrone Acetate
RxNorm normalized name: Estradiol/Norethindrone Acetate 1 MG-0.5 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT01462266
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to sitagliptin once daily for 24 weeks
Trial: NCT02027337
Drug: 20 mcg ethinylestradiol/3 mg drospirenone and Selmevit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Trial: NCT02027337
Drug: 30 mcg ethinylestradiol/3 mg drospirenone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
Trial: NCT02027337
Drug: 30 mcg ethinylestradiol/3 mg drospirenone and Selmevit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Trial: NCT00483730
Drug: Deproteinised hemoderivative of calf blood (Actovegin)
RxNorm normalized name: thymus gland-calf
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Symptomatic diabetic peripheral polyneuropathy
Trial: NCT00941785
Drug: DHA-PQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three monthly administrations of Duocotexcin (DHA-PQ):~dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days
Trial: NCT00941785
Drug: SP-AQ
RxNorm normalized name: SPS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:~One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg
Trial: NCT02027337
Drug: 35 mcg ethinylestradiol/2 mg cyproterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
Trial: NCT01680900
Drug: placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules matched to drug capsules.
Trial: NCT01915082
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):~Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Trial: NCT01915082
Drug: Ora-Plus
RxNorm normalized name: Ora-Plus Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):~Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31).
Trial: NCT04348409
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo BID for 7 days
Trial: NCT05683444
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Infusion
Trial: NCT00398463
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion will be administered for 14-24 hours
Trial: NCT02027337
Drug: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
Trial: NCT00898560
Drug: Microginon®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
Trial: NCT00318760
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule 1 dose
Trial: NCT02482129
Drug: LME636 Vehicle
RxNorm normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive ingredients used for masking purposes
Trial: NCT03887754
Drug: Non specific Multivitamin
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group received non specific multivitamins as placebo for 8 months.
Trial: NCT01318330
Drug: Homeo-GH
RxNorm normalized name: Urtica urens homeopathic preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
Trial: NCT01440179
Drug: SAR3419
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
Trial: NCT00415831
Drug: ELC200 (carbidopa+levodopa+entacapone)
RxNorm normalized name: carbidopa / entacapone / levodopa
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03123718
Drug: Intrathecal methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
Trial: NCT03123718
Drug: High-dose intravenous methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.~\* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged \>70 years.
Trial: NCT00919737
Drug: NPC-08
RxNorm normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polifeprosan 20 with Carmustine 3.85%
Trial: NCT00746421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200mg, 300mg or 400mg
Trial: NCT01845038
Drug: OTX-TPa ~4µg/day over 2 mos. with natural tears drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of \~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
Trial: NCT01845038
Drug: OTX-TPb ~3µg/day over 3 months with natural tears drops
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of \~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
Trial: NCT00913627
Drug: ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00913627
Drug: naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00913627
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01582308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
Trial: NCT00726687
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
Trial: NCT01229150
Drug: AZD6244
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
Trial: NCT01032213
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S received the same volume of isotonic saline as same method.
Trial: NCT01322321
Drug: ACZ885
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01322321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no